Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRXBiotechnology
-$0.05 today
- Market cap
- $792.52M
- Beta
- 1.07
- P/E (TTM)
- -30.5
- EPS (TTM)
- -$0.07
Volume 2.42M
Average 2.48M
Returns on capital
Lexicon Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-46.8%
avg -72.4%
ROIC
-28.7%
avg -40.5%
ROA
-27.2%
avg -35.3%
Analysis
ROA is currently the strongest return metric at -27.2% versus its period average of -35.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Michael Exton | Chief Executive Officer & Director | USD 1.15M | 56 | 328.50K | 0.07% |
Craig Granowitz | Senior Vice President & Chief Medical Officer | USD 789.54K | 61 | — | — |
Brian T. Crum | Senior Vice President, General Counsel & Secretary | USD 687.37K | 53 | 0 | <0.01% |
Scott Coiante | Senior Vice President & Chief Financial Officer | USD 646.29K | 59 | — | — |
Wendy E. McDermott | Senior Vice President of Human Resources | USD 580.45K | 55 | — | — |
Kristen L. Alexander | Vice President of Finance & Accounting | USD 379.81K | 58 | — | — |
Suma Gopinathan | Senior Vice President of Discovery | — | 53 | 0 | <0.01% |
Lisa DeFrancesco | Senior Vice President of Investor Relations & Corporate Communications | — | 46 | 24.67K | <0.01% |
Rachel Yap Martens | Senior Vice President & Chief Commercial Officer | — | 42 | 31.26K | <0.01% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
9
$2.77M
Sells
0
$0.00
Net Transaction Value
+$2.77M
Net buying
Most Active
DEBBANE RAYMOND
7 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 6, 26Nov 6, 2026 | Exton Michael Direct | Buy | $50K$49,999.44 |
| Feb 25, 26Feb 25, 2026 | DEBBANE RAYMOND Direct | Buy | $3K$2,980.00 |
| Feb 23, 26Feb 23, 2026 | DEBBANE RAYMOND Direct | Buy | $147K$147,000.00 |
| Feb 20, 26Feb 20, 2026 | DEBBANE RAYMOND Direct | Buy | $147.8K$147,790.00 |
| Feb 19, 26Feb 19, 2026 | DEBBANE RAYMOND Direct | Buy | $72K$71,965.00 |
| Feb 18, 26Feb 18, 2026 | DEBBANE RAYMOND Direct | Buy | $176.5K$176,468.16 |
| Feb 17, 26Feb 17, 2026 | DEBBANE RAYMOND Direct | Buy | $100.5K$100,544.33 |
| Feb 13, 26Feb 13, 2026 | DEBBANE RAYMOND Direct | Buy | $75.9K$75,876.55 |
| Feb 2, 26Feb 2, 2026 | Invus Global Management, LLC Indirect | Buy | $2M$2,000,000.60 |
Summary
Insiders reported 9 buys worth $2.77M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.77M. DEBBANE RAYMOND was the most active insider with 7 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +610.3% | +39.1% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +610.3% over three years. Forward estimates point to Revenue at +39.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Lexicon Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about LXRX's management, answered from reported figures.
Who manages LXRX?
Lexicon Pharmaceuticals, Inc. (LXRX) lists 9 active executives. The top listed executive is Craig Granowitz, Senior Vice President & Chief Medical Officer.
Are LXRX insiders buying or selling?
Recent insider activity shows net buying of $67.48M.
Continue the stock analysis
Jump to another research area for this company.